Stocktoria
RESMED INC RMD
RESMED INC (RMD) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.07% (safety: safe). FY2025 revenue was $5.1B at a 27.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.63 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-07 | RBC Capital | Sector Perform (main) |
| 2026-08-07 | Piper Sandler | Neutral (main) |
| 2026-08-07 | Keybanc | Overweight (main) |
| 2026-08-07 | Wells Fargo | Equal-Weight (main) |
| 2026-07-15 | Mizuho | Outperform (main) |
| 2026-07-13 | Citigroup | Neutral (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.304 |
| Retained earnings / assets | 0.744 |
| EBIT / assets | 0.206 |
| Equity / liabilities | 2.705 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RMD | RESMED INC | 8/9 | 8.65 | 20.7 | +9.8% |
| DXCM | DEXCOM INC | 7/9 | 4.98 | 32.4 | +15.6% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
About RESMED INC
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
FAQ
Is RMD financially healthy?
RESMED INC's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does RMD pay a dividend, and is it safe?
Yes. RESMED INC pays a dividend yielding about 1.07% with a 22.2% payout ratio, rated “safe” for safety.
How profitable is RMD?
In FY2025, RESMED INC had a net margin of 27.2% and a return on equity of 23.5%.
Is RMD overvalued or undervalued?
RESMED INC trades at about 23.8× trailing earnings — below its 10-year norm (10-year range 27.7×–83.9×, median 45.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for RMD?
The average Wall-Street price target for RESMED INC is $247.20, about 9.4% above the recent price, from 15 analysts (consensus: buy).
Is RMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RESMED INC: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 20.7×, a dividend yield of 1.07%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.